Status
Conditions
About
Significant advances in dedicated materials and techniques along with increased operator experience led to a significant increment in procedural success rate of peripheral endovascular interventions, exceeding 90% in expert hands with reported low procedural complication rates. However, there are still lack of data on procedural outcomes, in-hospital complications, and resource utilization on treatment of (complex) lesions in the femoral, popliteal and infrapopliteal artery in the real-world condition in Europe.
Full description
The study will enroll consecutive eligible subjects who have peripheral artery disease (PAD) requiring endovascular treatment of de-novo and restenotic atherosclerotic lesions in femoral, popliteal and infrapopliteal arteries.
The purpose of this prospective, multicenter, observational European Study is to evaluate the standard of care practices, procedural outcomes, and in-hospital complications of endovascular peripheral interventions for treatment of lesions in the femoral, popliteal and infrapopliteal arteries.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subject ≥18 years old
Subject has provided written informed consent
Subject has Rutherford classification 2 to 6
Reference vessel diameter ≥2 and ≤7 mm
Target lesion(s) has stenosis >70% by visual assessment
Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between the lesions will be considered one lesion.
For Above the knee (ATK) group
Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)
At least 1 below-knee artery patent to the ankle
Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care.
For Below the knee (BTK) group:
Target lesions involve arteries below the tibial plateau
Successful treatment of inflow vessel (from ipsilateral iliac to the target lesion) resulting in ≤30% residual stenosis with no evidence of embolization or significant complications.
Exclusion criteria
380 participants in 2 patient groups
Loading...
Central trial contact
Helene Kuissu, PharmD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal